Roche, OraSure accept FDA 510(k) hole for Oral Ichor Sedate Testing Group

OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche announced today that the U.S. Chow and Hallucinogenic Regulation (FDA) has granted the Companies 510(k) clearance on four identical fully automated oral fluid drugs of vituperation assays developed to be inured to exclusively as part of OraSure's Impede® Pronounced Unformed Dope Testing System. The cleared verbal watery assays count Phencyclidine (PCP), Cocaine, Opiates and Methamphetamine.

The spoken mutable assays practise Roche's KIMS (kinetic interaction of micro-particles in solution) technology and were jointly developed covered by an compact previously signed via the parties. These assays are designed to run on various clinical chemistry automated analyzers, which are intended to countenance vocal fluid samples to be processed with the selfsame efficiency as current fully automated urine-based drug tests.

We are acutely tickled pink to announce this valuable milestone in our honky-tonk stab with Roch e to improve and call these important drugs of vilify assays, said Douglas A. Michels, President and CEO of OraSure Technologies. The blend of Roche's commerce leadership in lab instrumentation and reagent chemistry and our operation in Order Risnia oral fluid technology and sample collection devices has enabled us to cause to market a breakthrough structure that inclination own an next and total contact on laboratory proficiency seeking drugs of abuse testing.

The confirmation of this in front fasten on of fully automated pronounced running drugs of abuse assays demonstrates the strengths and familiarity of both companies, said Unconstrained G. Sieben, SVP and Time D Director of Roche Expert Diagnostics. Specifically the technologies and expertise of our collective research and advance teams will enable us to stock up novel high-priced throughput verbal running soporific testing solutions.

The Companies anticipate the key four assays to be available for traffic later this year. A variety of additional assays are also in condition and are currently in varying stages of submission with the FDA.

Developed and manufactured through OraSure Technologies, the Intercept® Treatment Testing Process is the single FDA-cleared in vitro diagnostic laboratory-based said pliant testing system second-hand an eye to detecting commonly maltreated drugs such as marijuana, cocaine, opiates, PCP and amphetamines (including methamphetamine and ecstasy) and an eye to detecting barbiturates, methadone and benzodiazepines. All of these drugs of rail against assays are currently processed in laboratories using microplate technology. In collaboration with Roche, four of these assays â€" PCP, cocaine, opiates and methamphetamine â€" can instantly be processed efficiently using automated analyzers. Intercept® is predominantly tempered to in workplace, tranquillizer treatment and criminal punishment testin g markets, as admirably as in community kind systems.

A worldwide chairman in diagnostics, Roche has been providing testing solutions as a remedy for the drugs of malign call for more than 25 years. Roche offers a unshaded check-up menu, integrated analyzer platforms and automation solutions to stop a substantial variety of labs increase receipts, repair efficiency and lift tolerant care.